Filing Details
- Accession Number:
- 0001599901-26-000014
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2026-01-09 17:13:17
- Reporting Period:
- 2026-01-07
- Filing Date:
- 2026-01-09
- Accepted Time:
- 2026-01-09 17:13:17
- SEC Url:
- Form 4 Filing
- 10b5-1 trading plan:
- Yes
The filer marked this filing as including a trade under a Rule 10b5-1 trading arrangement.
A 10b5-1 plan sets trading instructions in advance, so trades follow those instructions instead of a new decision at the time of each trade. The checkbox applies to the filing as a whole and does not identify every covered trade; see the footnotes for details. It reflects the filer's disclosure, not SEC approval of the plan. SEC Form 4 instructions.
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1599901 | Avidity Biosciences Inc. | RNA | Pharmaceutical Preparations (2834) | 461336960 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1629383 | Sarah Boyce | C/O Avidity Biosciences, Inc. 3020 Callan Rd. San Diego CA 92121 | President and Ceo | Yes | Yes | No | No |
Transaction Summary
| Sold: | 8,576 shares | Avg. Price: $72.23 | Total Value: $619,444.48 |
| Number of Shares After Transactions: | 283,394 shares | ||
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2026-01-07 | 8,576 | $72.23 | 283,394 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 6, 2026 and the sale of the resulting shares of common stock on January 7, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1.
Hedge Fund Resource Center Billionaire Hedge Funds
